Abstract
BERLIN-- Biotech players hoping to stake claims on human stem cells or DNA sequences in Europe saw a couple of warning shots whiz across their bows last week. On 24 July, the European Patent Office strongly limited a controversial patent covering stem cell technology, striking out all references to human or animal embryonic stem cells. And a British think tank called on patent offices around the world to refrain from awarding patents on DNA sequences.

This publication has 0 references indexed in Scilit: